Pharmaceutical Drugs Industry Overview

Induced Pluripotent Stem Cell (iPSC) Market Definition

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as hepatocytes, fibroblasts, keratinocytes, and neurons. Induced pluripotent stem cell (iPSC) are derived from somatic cells such as skin or blood cells that have been reprogrammed, by ectopic introduction of transcriptional factor genes, back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes.

The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis (organizations, sole traders and partnerships) that provides treatment for alpha mannosidosis, which is a lysosomal storage disorder. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Alpha-mannosidosis is a rare genetic inherited condition that affects the organs and tissues of the person suffering from the disease. The treatment therapy focuses on detecting and preventing polysaccharide accumulations within mutant cells, which can cause harm to tissue, organs, and eventually death. Polysaccharides are defined as larger molecules composed of several linked sugar molecules. The main types of therapy for alpha mannosidosis are bone marrow transplant (BMT), enzyme replacement therapy (ERT), peripheral blood stem cell transplantation (PBSCT) and gene therapy. A bone marrow transplant is a procedure in which dysfunctional marrow is replaced with healthy marrow. Enzyme replacement therapy includes replacing a defective enzyme in people who are lacking or deficient in that enzyme. Peripheral blood stem cell transplantation is a procedure in which the patient whose stem cells that have been destroyed by disease or by the radiation or high doses of anticancer drugs, they receive healthy stem cells. Gene therapy is a procedure in when DNA is introduced into a patient to treat a genetic disease. The different types of indications include Type I, Type II and Type III and is implemented in wide range of verticals such as hospitals and specialty clinics. The global alpha mannosidosis market is expected to grow from $7.50 million in 2020 to $8.89 million in 2021 at a compound annual growth rate (CAGR) of 18.6%. The growth is mainly due to increasing prevalence of alpha mannosidosis, use of orphan drugs, fee reductions and tax credits, increasing investment in the rare disease treatment and advancements in treatment drugs. The alpha mannosidosis market is expected to reach $17.91 million in 2025 at a CAGR of 19.1%. The increasing investments on research is expected to contribute to the growth of the alpha mannosidosis market in the forecast period. Currently, in the alpha mannosidosis market, only one company has therapies for the rare genetic disease. However, several firms have products in the clinical stages, which will boost market demand in the forecast period. For instance, in 2020, the EU clinical trials database lists 39,219 clinical trials with a EudraCT protocol, 6,426 of which are clinical trials involving subjects under the age of 18. Therefore, the increasing investments on research fuels the growth of the alpha mannosidosis market. The advancements in treatment for alpha mannosidosis like pharmacological therapy are gaining traction in the alpha mannosidosis market. For instance, in 2018 – Chiesi Group, an international research-focused Healthcare company, announced that it has received a positive opinion recommending the marketing authorization of Velmanase Alfa, under the brand name Lamzede from the European Medicines Agency Committee for Medicinal Products for Human Use. Lamzede is an enzyme replacement therapy intended to provide or supplement natural alpha-mannosidase, an enzyme that helps with the degradation of mannose–rich oligosaccharides and thus prevents their accumulation in various tissues in the body. Major players in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex. North America was the largest region in the alpha mannosidosis market in 2020. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global alpha mannosidosis market is segmented - 1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy 2) By Indication: Type I, Type II, Type III 3) By End-User: Hospitals, Speciality Clinics

The gynecology drugs market consists of sales of gynecology drugs services by entities (organizations, sole traders, and partnerships) that manufacture gynecology drugs which are used to treat gynecological diseases which includes conditions affecting the uterus, ovaries, and their appendages. The main types of therapeutics in gynecology drugs are hormonal therapy and non-hormonal therapy. Hormonal therapy is a treatment that adds, blocks or removes hormones to slow or stop the growth of cancer cells that need hormones to grow. Non hormonal therapy involves the usage of anti- infective, anti-inflammatory agents, lubricants, moistures, antidepressants, gabapentin, clonidine and others. Gynecology drugs are used for gynecology cancers, menopausal disorder, polycystic ovary syndrome, contraception and others and distributed through hospital pharmacies, retail pharmacies and online pharmacies. The global gynecology drugs market is expected to grow from $22.22 billion in 2020 to $24.68 billion in 2021 at a compound annual growth rate (CAGR) of 11.07%. The growth is mainly due to the increase in gynecological disorders among women and rising cases of gynecological cancer. The gynecology drugs market is expected to reach $31.21 billion in 2025 at a CAGR of 6.05%. The rise in number of women suffering from ovarian cancer would drive the growth of the global gynecological drugs market. For instance, according to Globocan, it is estimated that the global incidence of ovarian cancer will increase from 295,414 in 2018 to 434,184 by 2040. The increasing incidence of ovarian cancer would boost the market for gynecological drugs in the forecast period. Alternative treatment methods and natural remedies are increasingly becoming popular globally which is expected to have a negative impact on the revenues of gynecological drugs companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses range of techniques and treatments for gynecological cancer. Many of herbs used in Ayurveda have anti-cancer properties, example Curcumin, Holy Basil are said to inhibit the growth of cancerous cells and Ayurvedic gynecological procedures like Agnikarma helps treat cervical erosion. This growing adoption of alternative treatments is expected to have a negative impact on the growth of the market. Drug manufacturers are investing in developing personalized cancer vaccines, including gynecological cancers, and few have reached clinical trial phases. Pharmaceutical companies are combining genetic sequencing and precision medicine to create new drug therapies and cancer treatments that are designed to treat specific patients. For instance, in 2016, Merck, an American pharmaceutical company collaborated with Moderna Therapeutics, an American biotech company pioneer of messenger RNA Therapeutics to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. In 2019, Moderna announced the result from the ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors. The results were positive when mRNA mRNA personalized cancer vaccine (PCV) mRNA-4157, given alone or in combination with Merck pembrolizumab (KEYTRUDA®). Currently the vaccine is in phase 2 clinical trial. In January 2020, India based capital market company True North announced the acquisition of India based Glenmark Pharmaceuticals Ltd gynecology business in India and Nepal for $16.2 million (INR 115 crore). Through this acquisition, True North aims at further growing the gynecology portfolio of Glenmark and expanding presence in multiple geographies. Major players in the gynecology drugs market are Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Allergan, AstraZeneca, Bayer AG, AbbVie, TherapeuticsMD Inc., Lupin Pharmaceuticals Inc., Ferring Holding SA, Johnson & Johnson, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., and Sanofi. North America was the largest region in the gynecology drugs market in 2020. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global gynecology drugs market is segmented - 1) By Therapeutics: Hormonal Therapy, Non-Hormonal Therapy 2) By Indication: Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, Others 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The fetal bovine serum market consists of sales of fetal bovine serum by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing fetal bovine serum and related services. Fetal bovine serum refers to the liquid fraction of clotted blood from fetal calves, with reduced cells, fibrin, and clotting factors. It has high concentration of nutritional and macromolecular factors essential for cell growth and is a critical raw material for animal care, biotechnology, drug development, diagnostics, and other fields of research. The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others. Charcoal stripped fetal bovine serum has activated carbon that helps lower levels of lipophilic compounds such as hormones, growth factors, and steroids and is used to conduct receptor or estrogen related studies. Dialyzed fetal bovine serum has reduced concentration of low molecular weight components such as nucleotides, amino acids, hormones, salts and various small proteins in serum and is used in cell culture systems requiring a more defined environment of small molecules. Exosome depleted fetal bovine serum isolates exosomes from cultured cells without the complication of bovine exosomes that are present in conventional FBS and is used for research on exosomes. The fetal bovine serum is used in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, others. Fetal bovine serum is used in various sectors including research and academic institutes, biotechnology and pharmaceutical industry, others. The global fetal bovine serum market is expected to grow from $855.80 million in 2020 to $946.25 million in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth in mainly due to increase in R&D towards development of novel biopharmaceuticals. The fetal bovine serum market is expected to reach $1,175.36 million in 2025 at a CAGR of 5.6%. The increasing demand for biopharmaceuticals is expected to drive the growth of the fetal bovine serum market in the forecast period. A biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology. Fetal bovine serum (FBS) is the most widely used substitute for animal cell culture media. Pharmaceutical firms, diagnostic laboratories, and researchers rely heavily on FBS for much of their cell culture requirements in biologics research. The global biologics market is expected to increase from $253.4 billion in 2020 to $420.5 billion by 2025. Therefore, the rising demand for biopharmaceuticals propels the growth of the fetal bovine serum market. Increasing collaborations between companies and research intuitions is a key trend gaining popularity in the fetal bovine serum market. Major companies are collaborating for increasing production capabilities, expanding market share and developing new products. For instance, in 2017, US based GE Healthcare collaborated with New Zealand based Oritain for developing an independent test that can confirm the country of origin of fetal bovine serum (FBS) which would help biomanufacturing entities as FBS used in different countries pose different risk levels for virus contamination. In December 2019, Sartorius, a German-based life science research and biopharmaceutical company acquired Biological Industries for $53.67 million. Through this acquisition, Sartorius expanded cell culture media and complementing the product portfolio for the users in the growing advanced therapies market in the majority portion of Biological Industries. Biological Industries is an Israel-based chemical and biotechnology company that provides fetal bovine serum for mammalian cell culture. Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc., Biowest, Bio-Techne, Rocky Mountain Biologicals Inc., Merck KGaA, TCS Biosciences Ltd, Bovogen Biologicals Pty Ltd, Tissue Culture Biologicals, Atlanta Biologicals Inc., Atlas Biologicals, Acess Biologicals, Animal Technologies Inc, Nucleus Biologics, Corning Incorporated, J R Scientific Inc., Cytiva, Axil Scientific Pte Ltd, and Moregate Biotech. North America was the largest region in the fetal bovine serum market in 2020. Asia Pacific recorded the fastest growth during the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Fetal Bovine Serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global fetal bovine serum market is segmented - 1) By Product: Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted, Stem Cell, Others 2) By Application: Drug Discovery, Cell Culture Media, In Vitro Fertilization, Human and Animal Vaccine Production, Diagnostics, Others 3) By End-User: Research And Academic Institutes, Biotechnology And Pharmaceutical Industry, Others

Dry Eye Medication Market Definition

The dry eye medication market consists of sales of dry eye drugs and other related services by entities (organizations, sole traders and partnerships) that manufacture dry eye medication (or drugs) used to treat dry eyes. The dry eye medication market covers drugs that are used in the treatment of diseases related to dry eyes, irritation, pain, and infection. Dry eye is one of the most common eye related medical conditions; for example, an estimated 25 million Americans suffer from at least one symptom of dry eyes. It can be defined as the inability of human eyes to produce or maintain a sufficient quantity and quality of natural tears to lubricate the eyes. This can result in damage to the surface of the eyes, leading to pain, irritation, and inflammation, increase the risk of eye infection, and affect a person’s vision. Common disorders caused by dry eyes include keratoconjunctivitis sicca, evaporative dry eye disease, and aqueous dry eye disease. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions, which are included in a separate report.

Apparel Market Definition

The acne drugs market consists of sales of acne drugs and related services by entities (organizations, sole traders and partnerships) that produce acne drugs to treat acne vulgaris. This industry includes establishments that produce drugs used in treating acne which is a common skin condition that results from the plugging of hair follicles with skin dead cells and sebum. Often more severe forms of the condition occur when the resulting build of bacteria leads to inflammation and infection.

Cell And Gene Therapy Market Definition

The cell and gene therapy market consists of sales of cell and gene therapies by entities that produce them. Cell and gene therapy work with similar therapeutic goals, targeting DNA or RNA inside or outside the body. These therapies modify genetic material to improve functioning or fight diseases. Genes are the basic physical and functional unit of heredity, received from one’s parents. Genes act as a code for the creation of all proteins in a living organism. Gene therapy seeks to manipulate a patient’s cells to alter the biological property of cells for the treatment of an inherited or acquired disease. It works by several mechanisms, including replacing a disease-causing gene with a healthy copy of the gene, inactivating an ill-functioning disease-causing gene, or introducing a modified gene into the body to treat diseases.

HIV Drugs Market Definition

The HIV drug market consists of sales of human immunodeficiency virus (HIV) drugs used for the treatment of HIV infection. The market consists of revenue generated by the anti-retroviral (ARV) drug companies manufacturing anti-retroviral drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs) for the treatment of a HIV infection.